TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Qualigen Therapeutics ( (QLGN) ) just unveiled an update.
On November 14, 2025, Qualigen Therapeutics, Inc. filed a Certificate of Amendment to change its corporate name to AIxCrypto Holdings, Inc., with plans to trade under the new ticker symbol ‘AIXC’ on the Nasdaq Capital Market. This transition marks a strategic shift from traditional biotechnology to a Web3-driven decentralized AI technology platform, with Faraday Future becoming the majority shareholder. The company aims to position itself as a leading gateway to the AI × Web3 era, unveiling a new business model and development roadmap during a Nasdaq ceremony on November 20, 2025.
Spark’s Take on QLGN Stock
According to Spark, TipRanks’ AI Analyst, QLGN is a Underperform.
Qualigen Therapeutics’ overall stock score is low due to significant financial challenges, including declining revenue, substantial losses, and financial instability. The bearish technical analysis further dampens the outlook. However, recent corporate events like strategic investments and leadership changes provide a slight positive outlook on future potential improvements.
To see Spark’s full report on QLGN stock, click here.
More about Qualigen Therapeutics
Qualigen Therapeutics, Inc. is a biotechnology company based in Carlsbad, California, focusing on developing and commercializing innovative oncology and immunology therapies. The company is also expanding into crypto asset and Web3 strategies, integrating advanced technology with capital market innovation to drive global growth and ecosystem expansion.
Average Trading Volume: 2,624,407
Technical Sentiment Signal: Strong Sell
Current Market Cap: $7.26M
Find detailed analytics on QLGN stock on TipRanks’ Stock Analysis page.